Accretion Nutraveda Peer Comparison

BSE: 544694

₹291.50

₹-4.50 (-1.52%)

As on 22-Sep-2026IST

Market cap

₹211 Cr

Revenue (TTM)

₹34 Cr

P/E Ratio

41.6

P/B Ratio

6.7

Div. Yield

0 %

Edit

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	211	37,585	28,859	16,982	16,312
Revenue (₹ Cr)	34	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	5.07	1,018.97	497.77	603.02	270.18
Net Margin (%)	15.03	10.47	20.72	22.63	23.29
RoE (%)	27.68	21.30	28.49	19.61	14.45
Price to Earnings	41.64	37.16	57.98	28.16	59.23
Price-To-Book	6.69	7.19	14.28	4.87	7.87

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	33.60	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	33.72	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	26.71	7,457.80	1,448.49	1,754.55	686.95
EBITDA	6.90	1,745.74	574.50	797.28	367.94
Depreciation	0.26	415.05	91.74	75.36	74.46
EBIT	6.64	1,330.70	482.76	721.93	293.48
Interest	0.54	143.67	23.95	5.37	0.82
Other Income	0.11	131.47	30.17	60.41	52.36
Exceptional Items	--	-31.35	--	-25.66	-3.28
Profit before Tax	6.21	1,287.14	488.98	751.31	344.65
Provision for Tax	1.14	345.87	124.98	186.83	85.42
Profit after Tax	5.07	941.27	364.00	564.48	259.23

Liabilities (₹ Cr)

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	35.47	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	--	26.64	--	--	-1.92
Non-Current Liabilities	3.78	584.19	345.47	142.73	47.58
Current Liabilities	2.53	3,912.24	710.20	682.24	169.08
Total Liabilities	41.78	9,514.48	2,930.14	4,157.10	2,231.79

Assets (₹ Cr)

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	7.61	3,861.01	1,447.01	1,333.54	981.68
Current Assets	30.26	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	41.78	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	4.23	1,204.08	196.61	0.00	0.00
Net Current Assets	27.74	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	--	258.92	13.18	4.82	3.76

Cashflow (₹ Cr)

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-9.42	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-14.50	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	25.19	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	1.26	93.92	-56.08	-69.08	11.28

Ratios

Profitability Ratios

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	30.19	25.25	27.50	24.61	18.04
ROE (%)	27.68	20.09	21.43	18.41	13.54
ROA (%)	19.38	10.70	14.25	14.27	12.15
EBIT Margin (%)	20.86	20.40	29.89	33.61	39.84
Net Margin (%)	15.03	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	15.86	14.44	22.53	24.81	31.63

Growth Ratios

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	110.00	16.56	36.98	6.91	-12.10
EBIT Growth (%)	87.91	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	102.66	33.05	39.94	16.24	-30.25
EPS Growth (%)	36.32	35.59	39.94	16.05	-29.80
Book Value Growth (%)	524.85	11.36	22.95	18.43	11.27

Valuation Ratios

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	29.71	32.73	42.34	21.18	40.73
Price / Book Value	4.77	6.13	8.23	3.60	5.27
Dividend Yield (%)	0.00	0.23	0.28	0.51	0.74
EV/EBITDA	20.70	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	150.56	30,257.56	15,412.11	11,956.86	10,627.92

Solvency Ratios

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.13	0.24	0.10	0.00	0.00
Short term debt to equity ratio	--	0.16	--	--	--
Current Ratio	11.98	1.43	2.09	4.14	7.39
Quick Ratio	8.42	0.82	1.37	3.12	5.46
Interest Coverage	12.57	9.96	21.42	140.86	419.57

Operating Efficiency Ratios

	Accretion Nutraveda	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	24.14	27.84	26.76	42.05	43.63
Asset Turnover	1.28	1.07	0.79	0.65	0.49
Receivable days	61.80	88.68	77.32	144.58	169.86
Inventory Days	73.78	84.11	80.83	96.67	97.92
Payable days	12.43	176.65	125.94	135.45	159.68
Cash Conversion Cycle	123.15	-3.86	32.22	105.80	108.11

Annual
Quarterly